The average follow-up time in GeNeSIS was relatively short (mean, 4.2 years for GH-treated patients) for consideration of conditions such as T2DM and cancer and only during childhood GH treatment, with the possibility that a higher risk may be revealed with longer GH treatment and/or follow-up. Here, GH1 is linked to type 2 diabetes mellitus.